SNUG01 showed favorable safety and signs of early clinical efficacy in a recently completed investigator-initiated trial in China, the firm said.

FRIDAY, Aug. 15, 2025 (HealthDay News) — For the first time, scientists have created a brain implant that can “hear” and ...

SineuGene Therapeutics Co., Ltd. ("SineuGene"), clinical-stage biotechnology company that mainly focuses on gene therapies for neurological disorders, announced today that China's National Medical ...

Earnings per share (GAAP) was $0.13 for Q2 2025, outperforming GAAP estimates for a loss of $0.23. Net loss (GAAP) fell to $11.2 million for Q2 2025, due to a significant gain from changes in warrant ...

Clene (NASDAQ: CLNN) , a late clinical-stage biopharma company developing treatments for neurodegenerative diseases, reported Q2 2025 results and sai ...